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Abstract 
Opioid misuse and overdose related deaths are an escalating problem in the nation that crosses 
all gender, age, sociologic, economic, and race barriers.  A private practice clinic treating chronic 
pain with opioid medication was the focus for a co-prescribing naloxone policy implementation.  
Over half of the patient sample was male, with an average age range of 51 to 60 years old and 
having obtained some level of college education.  The purpose of the policy was to provide 
patient education regarding the risks of opioid medication, naloxone education, and to improve 
provider barriers in prescribing naloxone.  The policy addressed this by removing the burden of 
risk stratification and applying the universal precautions model from infectious disease to 
chronic pain patients receiving opioid medications.  Ultimately, the increased patient education 
did not have a significant impact on the number of patients choosing to fill the naloxone 
prescription.  Future practice may include further examination of the patient barriers to filling the 
naloxone prescription and or including this in the narcotic contract to receive opioid medications 
to treat chronic pain.   
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Chapter One:  Overview of the Problem of Interest  
 Prescription drug overdose deaths are escalating in the state of North Carolina (NC).  
Opioid misuse can be a relatively easy term to define; however, identifying patients at risk for 
opioid misuse can be a more difficult task.  In the 2016 Center for Disease Control and 
Prevention (CDC) Guidelines for Prescribing Opioids to Chronic Pain Patients, 
recommendations for assessing risk factors and addressing potential harm are made, including 
the consideration of offering naloxone to high-risk patients (Dowell, Haegerich and Chou, 2016).  
Although this is only a recommendation, a universal precaution model for co-prescribing 
naloxone can have a significant impact on reducing opioid-related deaths and focusing on harm 
reduction.  A policy for providers to co-prescribe naloxone to any patient receiving chronic 
opioid medications is the most consistent way to improve the overdose risk for the chronic pain 
population and remove the burden of risk stratification.  
Background Information  
  Opioid misuse and overdoses affect an alarming number of the population crossing all barriers, 
including age, socioeconomic status, and geographical boundaries. In 2010, there were 16,651 
reports of overdose deaths, then growing to 65,000 in 2016 (Soelberg, Brown, Vivier, Meyer & 
Ramachandran, 2017).  That is over a 200% increase in six short years.  In 2011, Cheatle (2015) 
reported 488,004 emergency room visits related to the nonmedical use of opioid medications.  
There is a problem regarding opioid usage in society that includes not only prescribing practices 
but also utilizing the medicines appropriately.  One way to help reduce harm in the chronic pain 
patient population is to increase access to naloxone.  Thus far, there are only recommendations to 
co-prescribe naloxone for harm reduction, including only prescribing to high-risk patients from 
the CDC (Dowel et al., 2016).  This recommendation would not benefit the patients who take the 
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medication for nonmedical reasons, recreational use, or take someone else's prescribed 
medications.  By only co-prescribing naloxone to these identified high-risk patients, the 
emergency room will continue to have a high number of visits and overdose deaths will continue. 
 Healthy People 2020 focuses on reducing nonmedical use of pain relievers as one of the 
objectives due to opioid misuse being a widespread issue in today's society (Healthy People 
2020, n.d.). The National Survey on Drug Use and Health reported that 53% of patients misusing 
opioid medications had obtained the medication from a friend or relative that received the opioid 
directly from one doctor between 2012 and 2013, meaning obtaining the drugs via doctor 
shopping was not the case (Takeda et al., 2016).  Doctor shopping is defined by the Center for 
Disease Control and Prevention as "a patient obtaining controlled substances from multiple 
healthcare practitioners without the prescriber's knowledge of the other prescriptions” (CDC, 
2012, p. 1).  One may imply that the opioid was obtained legitimately by a patient to treat pain. 
However, the prescriber was unaware of the patient's intent to misuse the prescription for an 
opioid. 
 Opioid misuse goes well beyond the initial patient who may have been receiving the 
medication for a legitimate purpose and prescribed the drug.  The behavior of sharing 
medications is difficult to screen for or catch in many patients.  Random pill counts, urine 
toxicology screens cannot account for one pill that may have been taken by a visiting friend or 
relative, for example. Fifty-three percent of the 11.5 million people aged 12 and older misused a 
prescription pain reliever given by, bought from or took the medication unknowingly from a 
friend or relative per the National Survey of Drug Use and Health in 2016 (Alder & Mallick-
Searle, 2018). 
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            Access to naloxone can positively impact the number of opioid-related deaths with 
consistent co-prescribing and patient education from providers.  Currently, the barriers to co-
prescribing naloxone include time limitations within patient visits, lack of knowledge regarding 
how to prescribe the medication, lack of consistent guidelines for the assessment of and 
identifying high-risk patients, patient cost, and lack of patient education materials.  Past research 
reveals that providers' logistical and attitudinal barriers were vital to overcoming the lack of co-
prescribing naloxone (Mueller, Koester, Glanz, Gardner, & Binswanger, 2016). Providers are not 
always comfortable discussing risk factors with many of their patients, especially on initial visits 
before establishing a patient-provider relationship.  Education is an essential component of 
overcoming the patient and provider barriers for naloxone co-prescribing (Mueller et al., 2016).    
 Provider and nursing education for the risks of opioid medication in pain management 
can have a significant impact on positive patient outcomes.  The limited education currently 
provided to patients regarding opioid risks and naloxone is a barrier that can be improved by 
consistency from the provider (Mueller et al., 2016).  The universal precautions model used by 
the University of New Mexico's Pain Center Study for co-prescribing naloxone rescue kits to all 
patients on opioid therapy for chronic non-cancer pain found no opioid-related deaths after the 
education of the patient and family (Takeda et al., 2016).   When applied to the pain population, 
the universal precautions model means that the naloxone is prescribed to each patient receiving a 
prescription for opioid medication, rather than being based on the risk evaluation.   Therefore, 
removing the burden of risk stratification for the provider.  Gourlay and Heit (2009) state that the 
universal precautions model is the most accurate way to decrease risk in the chronic pain 
population receiving opioid medications due to recognizing the impossibility of accurate risk 
assessment at the initial visit. 
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 "It is important to note that universal precautions are not simply about opioid prescribing, 
although it does highlight the value inherent in managing risk in all patients" (Gourlay & Heit, 
20019, p. S116).   For example, a patient is not likely to be one hundred percent forthcoming or 
honest at an initial visit regarding complete health history.  Therefore, this impacts the ability of 
the provider to assess any risk factors accurately.  The idea of managing risk in all patients, 
compared to the medication, is a significant finding; adoption of this model in an ambulatory 
setting is a useful public health intervention in private practice in eastern NC.   Gourlay and Heit 
also highlight the fact that there is no reliable data to support chronic opioid therapy prescribed 
for cancer versus non-cancer pain and co-occurring opioid misuse or overdose risk (2009).  
Patients receiving opioid therapy for cancer pain are not at any less of a risk for opioid overdose 
in comparison to the non-cancer pain patient population.  Using the universal precautions 
method, this patient population that can be difficult to treat as a provider has the potential for 
better outcomes and decreases patient harm. 
Significance of Clinical Problem  
 Currently, the CDC Guidelines for Opioid Prescribing for Chronic Pain Patients 
recommend naloxone prescribing for those who are at high risk for opioid therapy (Dowell et al., 
2015).  Currently, the Opioid Risk Assessment Tool is the screening tool for high-risk behavior 
for all patients. However, naloxone co-prescribing is inconsistent with each provider due to a 
lack of guidelines or policy.  Implementing a naloxone co-prescribing policy, including patient 
and family education, will help create consistency within the provider group, potentially 
improving patient outcomes, and harm reduction in this patient population.  The proposed Doctor 
of Nursing Practice (DNP) Project is to implement a naloxone co-prescribing policy for the 
providers using a universal precautions model.  Naloxone co-prescribing is a current gap in 
CO-PRESCRIBING NALOXONE POLICY 14 
practice and is an essential component for treating the pain patient population utilizing chronic 
opioid therapy.  There is intense scrutiny of pain management practice with the current opioid 
crisis from governing bodies, and harm reduction is a critical component.  For the patients on 
chronic opioid therapy, the risk of overdose is the most significant harm.  However, by placing 
the focus on individual risk factors, there is an inhibition of naloxone prescribing due to the 
target of patient behavior.  Removing the focus on individual risk factors reinforces the value of 
standardized or universal naloxone prescribing by lessening provider fears of offending a patient 
or medical-legal consequences (Binswanger et al., 2015). 
Question Guiding Inquiry (PICO)  
 The importance of naloxone co-prescribing for the organization is to consistently reduce 
harm in the chronic pain population receiving chronic opioid medication and potentially reduce 
the number of opioid-related deaths in the community.  In 2017, the National Institute on Drug 
Abuse (n.d.) reported that 1,953 overdose deaths occurred in the state of NC, a rate of 19.8 per 
100,000, and higher than the national average of 14.6 per 100,000.  North Carolina had a higher 
number of opioid prescriptions written by providers than the national average (National Institute 
on Drug Abuse, n.d.).  These numbers increase the average healthcare cost in NC and illustrate 
the need for harm reduction in this patient population. 
 Population. The target population for this proposed DNP project is the providers and 
nursing staff.  The providers include five physicians, two nurse practitioners, and five registered 
nurses that rotate in the clinic. 
Intervention. A universal precautions model will be used to implement a naloxone co-
prescribing policy for providers for each patient receiving opioid medication for chronic pain.  
The policy will be a universal approach to harm reduction and include patient education provided 
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by the nurse the day the provider writes the initial prescription.  The providers will receive 
education regarding the new policy in a staff meeting. 
Comparison. There will not be a data comparison for the reason that this is a policy 
implementation project.  The policy outcome measures will depend on the providers and nursing 
staff's adherence after implementation and are independent of any information before the policy. 
Outcome(s).  The intended outcomes are improved naloxone co-prescribing, improved 
patient knowledge regarding when and how to use naloxone, and actual filling of the prescription 
by the patient.   The three identified measurable outcomes would determine if providers follow 
the co-prescribing policy universally to all chronic pain patients receiving opioid therapy and if 
the policy is effective for the chronic pain population to increase access to naloxone. 
Summary  
 The chronic pain population treated with opioid therapy is at high risk for opioid-related 
overdose and death.  Unfortunately, it is not always the patient with a valid prescription for an 
opioid that misuses the medication with an adverse outcome such as an overdose.  Utilizing a 
universal precaution model for co-prescribing naloxone is effective in harm reduction in this 
patient population (Takeda et al., 2016).  "This model can be a simple, streamlined and valuable 
addition to most ambulatory settings- especially pain clinics and primary care sites where 
chronic opioid therapy is prescribed" (Takeda et al., 2016, p. 9).  Barriers to co-prescribing 
naloxone may include provider and patient education as well as previous experience. These 
barriers can be overcome with a policy in place to ensure consistency between providers in a 
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Chapter Two:  Review of the Literature  
One of the attributing factors to the opioid epidemic of recent years is the number of 
opioid medications prescribed in the United States when compared to other countries.  The 
number of prescriptions for opioid medications directly impacts the number of opioid 
medications that are misused, highlighting the risk factors due to the increased availability of the 
medicines.  The most significant risk of opioid misuse is an overdose.  Implementing a universal 
precautions model for prescribing naloxone to each patient receiving chronic opioid therapy can 
significantly impact the number of adverse outcomes and overall harm reduction.  A literature 
review for naloxone prescribing in a universal precaution manner finds supportive evidence for 
harm reduction. 
Literature Appraisal Methodology  
Sampling strategies.  A literature search was conducted on ECU Laupus Library's "one 
search" bar initially using the search terms naloxone, co-prescribing, and universal precautions.  
The inclusion of the term provider education and the other terms did not return any articles. 
Therefore, removing provider education from the initial search.  The search then returned 16 
items, including databases OVID, PubMed, CINAHL, and MEDLINE. Then, it conducted a 
second search utilizing the same keywords on Google Scholar returning 53 articles.  After 
review, 37 articles remained, and after removing duplicate results for the same search terms (see 
appendix A).   
Evaluation criteria.  The parameters for the search included English as the primary 
language and articles within the past ten years.  Opening the search for the past ten years was 
beneficial due to the limited information for the universal precautions model and application to 
pain management.  The literature search was limited to articles within the past five years for 
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research related to policy implementation.   This limitation excluded six of the articles, and 31 
remaining to review the full text.  Articles included both primary care settings and specialty 
clinics; the type of clinic was an excluding factor.   
Articles excluded in this process focused on universal precautions not related to 
managing the pain patient, naloxone prescribing, and those that did not focus directly on 
prescribing an opioid medication.  Then applying the exclusion criterion to the search, seven 
articles remained for a full review.  The seven articles remaining were directly related to 
prescribing naloxone, chronic opioid medication prescribing policies and guidelines, and harm 
reduction in this patient population.  The seven articles vary in level of evidence, including 
systematic reviews, expert opinions, and descriptive/qualitative studies as Melnyk defines the 
levels of evidence for research in nursing (Melnyk and Fineout-Overholt, 2015) (see Appendix 
B).  Melnyk and Fineout-Overholt (2015) described seven levels of evidence; systematic review 
and meta-analysis of randomized controlled trials resulting in practice guidelines, one or more 
randomized controlled trial, controlled trial with no randomization, case-control or cohort study, 
systematic review of descriptive and qualitative studies, single descriptive or qualitative study 
and finally expert opinion.   
Literature Review Findings  
  Overdose potential is multifaceted and can include behaviors such as overtaking the 
prescribed medication or also taking the medication in combination with other prescribed or not 
prescribed medications that create a synergistic effect on the central nervous system.  Anesthesia 
Analgesia published a literature review, The US Opioid Crisis: Current Federal and State Legal 
Issues, which reveals staggering numbers in the increasing number of overdose deaths from 
prescribed opioids in 2010. The literature review found that 16,651 overdose deaths documented, 
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growing to 65,000 in 2016, increasing the number of emergency room visits by over 200% in the 
short period (Soelberg et al., 2017).  The staggering numbers prompted many states to invoke 
easy access to naloxone in pharmacies without requiring a prescription from a provider.  
Multiple studies demonstrate a direct correlation between opioid dose and the risk of overdose, 
reinforcing the importance of appropriate patient selection and risk factor evaluation.  
  The diversion of prescription drugs, opioids specifically, has had a drastic impact on our 
society.  Data collected from the state and national level reveal that diversion of prescription 
opioids has been the most significant contributing factor for the increase in the number of 
overdoses in our country.  For an opioid medication to reach the street, for example, it has to 
start with a prescription rendered to a patient or, in other terms, a patient has to seek care for 
pain.  Often, medications that are not needed or leftover after a surgical procedure end up in a 
medicine cabinet and forgotten until a child, caretaker, or houseguest finds the remaining pills.  
The owner of the medication may never know the medication is gone.   An opioid medication 
may have been inadvertently taken from the patient's home and subsequently sold or taken by 
someone without a prescription for the medication.  Taking medications prescribed to others can 
result in an overdose or other adverse events.   
Level one evidence, as defined as clinical guidelines based on a systematic review of 
literature, was found in the literature review to support the reduction in harm by utilizing 
universal precautions prescribing model for naloxone, meaning prescribe naloxone to all patients 
on chronic opioid therapy regardless of risk factor (Melnyk & Fineout-Overholt, 2015).  
Gourlay, Heit, and Almahrezi (2005) include research from infectious disease and state that a 
reasonable approach to reducing the risk of transmission of life-threatening diseases to healthcare 
professionals was to take a basic level of precaution to all patients, including hepatitis B, 
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hepatitis C, and human immunodeficiency virus.  This universal precautions model approach to 
the pain population can improve patient outcomes due to the difficulty in accessing risk, and 
after the realization that it is impossible to assess risk entirely and accurately (Gourlay, Heit, and 
Almahrezi, 2005).   Accurately assessing risk in the chronic pain population is nearly impossible.  
There is no evidence to support increase harm in prescribing naloxone to any patient, although 
there is provider apprehension that naloxone may encourage drug abuse.  The most significant 
limitations found in the literature review were that of the provider.  Limitations including a lack 
of knowledge of how or when to prescribe naloxone or the apprehension that the patient may feel 
targeted when prescribed the rescue drug, and lastly, the naloxone can facilitate the abuse of an 
opioid. 
The 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain finds that opioid 
therapy significantly increases the risk of an opioid use disorder, overdose, and death with dose-
dependent effects (Dowell et al., 2016).  However, after review, Dowell et al.  (2016) presented 
the data as Type 3 evidence meaning there were notable limitations to the randomized and 
observational clinical trials.  However, one of the CDC's twelve recommendations is to assess 
risk and address harms, which includes prescribing naloxone when indicated to high-risk patients 
(Dowell et al., 2016).  The CDC identifies patients at high risk as patients at risk for opioid 
overdose, including a history of overdose, a history of substance abuse disorder, and high-dose 
opioids of morphine equivalents higher than 50 milligrams total daily dose or concurrent 
benzodiazepine use (Dowell et al., 2016).  The recommendations did not include how to 
appropriately assess risk other than an evaluation of the patient history of substance abuse, 
history of overdose, high dose narcotics over 50 daily morphine equivalents, or concurrent 
benzodiazepine use (Dowell et al., 2016).  This information is highly dependent on a reliable 
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patient interview, which is not always the case in this patient population, especially at an initial 
visit without the patient-provider relationship yet established.  The chronic use of opioid 
medications significantly increases the risk of overdose potential; this is unequivocal in the 
literature. However, patient-specific risk is more difficult to access accurately. 
The prevalence of opioid misuse is significant in the United States (US), as evidenced by 
the number of related opioid overdoses that have more than quadrupled over the past five years 
based on the CDC Statistics and National Drug Abuse Survey (Katzman et al., 2018).  The 
definition of opioid misuse is “defined as the intentional therapeutic use of a drug in an 
inappropriate way while in contrast abuse was defined as an intentional, nontherapeutic use of a 
drug or substance for the purpose of achieving a desirable psychological or physiological effect” 
(Cheatle, 2015, p. S4). The literature supports the co-prescribing of naloxone for any patient 
receiving chronic opioid therapy.   By prescribing naloxone to every patient, the question of how 
or when to prescribe naloxone is not part of the decision making process.  The universal 
precautions model also effectively and adequately removes the need for providers to assess risk 
factors for each patient presenting for evaluation, immediately removing two of the provider 
barriers to prescribing naloxone.  
Each of the studies included in the literature review had a similar intervention by 
prescribing naloxone to patients receiving chronic opioid therapy. Nursing education was a focus 
in addition to the prescription of naloxone in the study by Costello and Thompson (2015).  This 
study found that the significant gap in nursing knowledge impacts patient outcomes due to the 
patient not receiving accurate information.  Nursing education regarding opioid medications, 
including patient risks and benefits, positively impacted patient-related outcomes, specifically 
focusing on the risk of overdose.  The findings include that nursing education significantly 
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reduces harm in this patient population in combination with naloxone prescribing.  For this 
reason, the nursing education component is essential in the proposed co-prescribing policy 
proposal. 
Limitations of the Literature Review Process  
The literature review process highlights some limitations to a universal precautions 
approach to prescribing naloxone to chronic pain patients.  Costello and Thompson (2014) found 
that a significant limitation to their study was the sample size and the lack of similar studies for 
comparison when evaluating the nurse's role in patient education for co-prescribing naloxone.  
Other limitations identified in the literature review include findings that may not be generalizable 
to other settings, including a community at large as the target population versus the small cohorts 
used for many studies.  Due to the Health Insurance Portability and Accountability Act (HIPAA), 
direct outcome measures of the community members who received the naloxone are not 
achievable (Katzman et al., 2018).   Tracking the administration of naloxone is difficult and may 
not correlate with the patient filling the prescription.  Another limiting factor includes Katzman 
et al. (2016) findings that there is a lack of consistency when evaluating the provider's ability to 
identifying risk factors.   Depending upon medical and psychosocial conditions, the risk of a 
drug overdose death and aberrant behaviors can be fluid and ever-changing.  Risk mitigation is 
ongoing for the chronic pain population. Circumstances change, as do patient intentions with 
time, and find that evaluation of risk factors cannot merely be accurate with one visit.  Providers 
should be addressing risk factors on every visit.  A limitation of the literature review includes 
that the studies are a snapshot of a moment in time in an evolving problem in this patient 
population. Risk evaluation is an ongoing process throughout the patient-provider relationship.  
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Discussion 
Conclusion of findings.  The literature review for co-prescribing naloxone for patients 
receiving chronic pain medications is supportive of the intervention for harm reduction in the 
patient population.  The CDC has put forth guidelines for prescribing opioid medication in 2016 
that includes prescribing naloxone for patients receiving opioid medication found to be at risk of 
overdose. It is not clear how to appropriately assess patient risk.   The literature review does 
support prescribing naloxone to all patients receiving opioids rather than based on the risk or 
behavior focus of the individual patient.   The ultimate goal is harm reduction, decreasing the 
risk of overdose and opioid misuse.   
A key component for a successful policy to be implemented is education for the provider 
and the patient.  The provider education can improve many of the barriers to prescribing 
naloxone, including knowing when and how to prescribe naloxone and the fear of medical-legal 
issues and patients feeling targeted receiving a prescription.  Patient education is essential 
regarding the correct use of naloxone and how to identify an opioid overdose.  Implementing a 
universal precautions model to prescribe naloxone to all chronic pain patients with a prescription 
for an opioid medication removes the barriers to care and improves patient outcomes.  The 
removal of these barriers is beneficial for providers caring for a patient population that can be 
difficult to care for safely and effectively.   
Advantages and disadvantages of findings.  The advantages of the literature search 
findings include guidance in applying the universal precautions model to a naloxone co-
prescribing policy.  The literature also highlights the importance of the education component of 
prescribing naloxone and that it is essential for successful patient recognition of when and how 
to use the medication.   The patient education component of the policy will significantly improve 
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patient outcomes as evidence of the previous research.  The disadvantages of the proposed 
naloxone co-prescribing policy that the literature search reveals did support the apprehension of 
providers prescribing the medication for reasons including lack of knowledge and fears; this may 
affect provider compliance with the new policy implementation.    
Utilization of findings in practice change.  The implementation of The Policy for Co-
prescribing Naloxone for Chronic Pain Patients Receiving Opioid Medications and utilization by 
all providers in the clinic will be effective on the implementation date.  The targeted environment 
will be an interventional pain clinic.  Before the implementation date, a clinic meeting will be 
held with all the nursing staff to provide staff education for the policy and the nursing education 
role that is a vital component for the success of decreasing patient harm with prescribing opioid 
medications.  A vital component of the nursing education is informing patients of the risks of 
opioid medications, identifying an overdose, and when/how to use the naloxone.   A new patient 
may choose not to reveal a history of substance abuse for many reasons on an initial visit.  It will 
be essential to clarify the universal precautions model of the co-prescribing naloxone policy for 
the staff.  The literature supports that the nursing education component is essential for patients to 
know how and when to use the naloxone potentially.  Once the nursing staff education is 
complete, a provider meeting will be the next step to review the policy and answer any questions 
or concerns.  The objective will be a policy applied to all patients receiving an opioid 
medication.  Beyond the education component, the literature does not support a specific 
implementation of a universal precaution model for new policies. 
Summary  
The proposed Co-Prescribing Naloxone Policy planning and implementation as a clinic 
policy can occur after completing nursing and provider education.  The universal precautions 
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model will be used to implement the policy in the interventional pain clinic. Prescribing 
naloxone based on patient-specific risk factors will no longer be current practice; instead, 
prescribing naloxone due to the focus on the risk factor than an opioid medication prescribed.  
One of the objectives for Healthy People 2020 is to reduce the number of opioid-related 
overdose deaths; this number has been steadily increasing over the past ten years.  North 
Carolina has 25.1 deaths per 100,000 and is higher than the United States, with 22.8 deaths per 
100,000 (Healthy People 2020, n. d.).  The universal precautions approach to applying the co-
prescribing naloxone policy will impact a higher number of people our population beyond the 
pain population.  With consistency, the policy will improve patient outcomes and harm reduction 
with nursing education. Policy compliance will improve the overall patient experience removing 
the stigma of a naloxone prescription and improving understanding of the risks of opioid 
medications.  The policy will also achieve harm reduction in the patient's pain population by 
decreasing the risk of overdose deaths. There potentially should be a decrease in healthcare costs 
with a decrease in emergency room visits due to opioid misuse.   The aspects of co-prescribing 
naloxone to chronic pain patients receiving opioid medications accomplishes all three goals of 
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Chapter Three:  Theory and Concept Model for Evidence-based Practice  
Health care change is grounded in a theoretical framework.  Nola Pender is a nursing 
theorist that first appeared in nursing literature in 1982, and has been utilized in healthcare 
studies for over 27 years.  The primary focus of Pender’s health promotion model is to identify 
the behavioral factors influencing health behavior and pursuing a change in behavior to achieve a 
healthy lifestyle (Pender, 2011).  The application of health promotion nursing theory to the 
PRECEDE-PROCEED model to implement health care policy as a planning tool to guide the 
Naloxone Co-Prescribing Policy implementation and evaluation for this policy.  The PRECEDE-
PROCEED Model is used to design health programs efficiently, including program planners, 
policymakers, and analyze situations to improve health care outcomes.  The model includes eight 
phases for identifying, planning policy implementation, and review.    
Concept Analysis  
 The literature review identified key terms and concepts throughout the DNP project.   
The terms include universal prescribing, co-prescribing, opioid misuse, opioid abuse, overdose, 
and substance abuse.  The idea of universal prescribing for naloxone models the universal 
precautions from infectious disease and patient care.  Infectious disease was the first specialty to 
apply the same precautions to each patient regardless of a known diagnosis of transmittable 
infection to the provider or others, meaning the treatment of each patient with the same 
precautions regardless of diagnosis known or unknown.  An example of this is wearing gloves 
for each patient with a blood draw.  The idea of universal precautions not only improves patient 
care but also takes away the task of the provider assessing risk for each patient.  The application 
of the universal precautions model for patients on opioid therapy is to prescribe naloxone to each 
patient receiving an opioid, removing the task of assessing risk for the provider, therefor the 
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patient does not feel targeted.  The universal prescribing model leads to the concept of co-
prescribing, simply meaning prescribing an opioid and naloxone together each time. 
 In clinical practice, the concept of opioid misuse applies when evaluating the patient for 
addiction, overdose risk, side effects, attributing social factors, quality of life measures, opioid 
risk tools, and barriers to care.  For a provider to safely and adequately treat a patient with 
chronic pain, a thorough evaluation of patient risk must include opioid misuse potential.   The 
concept does not exist without each application or component.    
  Each of the articles stresses the importance of appropriate definitions regarding the terms 
associated with opioid misuse to understand the concept fully.   Many of the terms defined also 
are identifying the uses of the concept of opioid misuse.  As described in the comprehensive 
review published by Kaye, et al., misuse is defined as the "use of a medication for nonmedical 
use, or for reasons other than prescribed (2017).  Misuse can be willful or unintentional use of a 
substance in a manner not consistent with legal or medical guidelines, such as altering dosing or 
sharing medicines, which has harmful or potentially harmful consequences. It does not refer to 
use for mind-altering purposes" (Kaye et al., 2017, p. S95).   This concept can be used to 
evaluate further multiple issues with prescribing opioids, including substance abuse disorder, 
tolerance, physical dependence, addiction, aberrant drug-related behavior, abuse, diversion, and 
withdrawal.     
 The literature review consistently identifies the many contributing attributes to the 
concept of opioid misuse.   First and foremost, the purpose of prescribing an opioid is to treat the 
patient's pain utilizing evidence-based guidelines.  However, beyond the use of treating pain, 
other things must be considered, including addiction, quality of life, overdose potential, 
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diversion, side effects, social impact, and barriers to care.  Clarification of the identified terms 
defines many of the risk factors for chronic pain patients receiving opioid medications.   
Addiction is a component of opioid misuse that is misunderstood with other common terms such 
as tolerance and physical dependence.  For many providers, addiction is a significant concern for 
their patients.  Kaye, et al. define addiction as,  
A primary, chronic, neuro-biologic disease with genetic, psychosocial, and environmental 
factors influencing its development and manifestations.  It is characterized by behaviors 
that include one or more of the following; impaired control over drug use, compulsive 
use, continued use despite harm, and craving (2017, p. S95).    
The term addiction is commonly confused with physical dependence.  In general, physical 
dependence differs from addiction in that abrupt cessation of the drug may produce withdrawal 
syndrome (Kaye, et al., 2017).  Physical dependence occurs naturally and is not dependent on 
patient compliance of the medication rather consistent use of an opioid.       
The definition of physical dependence is similar to the tolerance of an opioid that Kaye, 
et al. defines as, "a state of adaption in which markedly increased drug doses are required to 
achieve the desired effect or exposure results in diminution of one or more opioid effects over 
time" (2017, p. S95).  Clinically, when treating a patient with chronic opioid therapy, physical 
dependence and tolerance will naturally occur.  However, addiction is a characterized behavior 
that does not routinely happen in patients prescribed opioid medications.  As a provider, it is 
essential to know the difference between the terms of physical dependence, tolerance, and 
addiction.  A clear understanding decreases the fear or concern of addiction does not create a 
barrier to caring for a patient that may be showing signs of tolerance to a medication that has 
been prescribed over the past two years for example.  Clinically the patient may present with 
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increased pain, seeking or asking for medication and can easily be labeled as a drug seeker.  
However, in reality, that patient is tolerant of the current dose of medication, and it may no 
longer provide a therapeutic effect. 
Theoretical Framework  
 Naming the Theory.  Nola Pender’s health promotion model is grounded in 
understanding the determinants of health behaviors to promote a healthy lifestyle in the focus 
population.   Pender identifies eight significant factors that influence health behavior that nursing 
can identify, providing eight opportunities for nursing interventions (Pender, 2011).  Pender 
explains that the person and environment are heavily intertwined; however, manipulation of the 
environment for health-enhancing behavior influences outcomes, including social and cultural 
guidance and cues (Pender, 2011).   Pender states that the relationship between the person and 
the environment is reciprocal, further saying that characteristics and life experiences shape all 
behaviors, including those that involve health (Pender, 2011). Pender defines health as "the 
actualization of inherent and acquired human potential through goal-directed behavior, 
competent self-care, and satisfying relationships with others, while adjustments are made as 
needed to maintain structural integrity and harmony with relevant environments" (Pender, 2011, 
p. 3).   Nursing can create a favorable condition for optimal health for the individual by 
collaborating with the individual, families, and community, as stated by Pender (2011).   
However, there is also an awareness that situational and interpersonal influences can impact 
health in a positive or negative outcome regarding health behavior (2011). 
 The health promotion model applies to many obesity studies and nutritional behavior in the 
literature.  It has not been used in research for naloxone co-prescribing based on the research. 
However, there are many components to the health promotion model that make it applicable to 
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this patient population.  One of the assumptions of the health promotion model is that individuals 
seek to regulate their behavior (Pender, 2011).  There is a portion of the opioid crisis that is due 
to social determinants, such as coping mechanisms for other health issues such as untreated 
mental health or cancer diagnosis.   The policy for co-prescribing naloxone to all patient patients 
promotes the goal-directed behavior of harm reduction and self-care.  The policy promotes 
healthy behavior with the desired end-point of health decision making and preparation for action 
resulting in harm reduction and improved health. 
Application to practice change.  The application of the health promotion model to the 
co-prescribing naloxone policy applies by targeting a specific risk/behavior to improve health 
outcomes in the chronic pain population.  The policy addresses specific benefits and potential 
barriers incorporating many aspects of patient care, including the provider, family, peers, and the 
community to commit to a plan of action and decrease the risk of harm for potential opioid 
overdose addressing many components of the model.  One of Pender's theoretical statements 
supports decreasing barriers and improving family involvement.   "Families, peers, and health 
care providers are important sources of interpersonal influence that can increase or decrease 
commitment to and engagement in health-promoting behavior" (Pender, 2011, p 5).   The 
literature review for naloxone co-prescribing does consistently identify the importance of patient 
education and family education for the use of naloxone.  The education for chronic opioid 
therapy for patients also implies a requirement for patients to thoroughly understand the risk of 
taking opioid medications, and the potential for an adverse outcome such as an overdose for 
health promotion behavior to exist.  Provider education is also identified as an essential part of 
co-prescribing naloxone to help mitigate medical-legal fears of prescribing the medication, how 
to prescribe the medication, and risk assessment of the pain patient. 
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Figure 3.1: This figure outlines Pender’s Health Promotion Model as it applies to The Policy for 
Co-Prescribing Naloxone with Opioid Medications. 
EBP Change Theory  
Naming the Change Model.  The PRECEDE-PROCEED Model is utilized to create a 
cost-benefit evaluation framework in health care to design effective programs and policies by 
guiding initial attention to outcomes rather than the input and using the theoretical framework 
from the health promotion model from Nola Pender.   The PRECEDE-PROCEED model has 
eight phases that are influenced by the individual and environmental factors, and, has been used 
as a planning tool with predictive validity (Green, n. d.).   
PRECEDE is an acronym for Predisposing, Reinforcing, and Enabling Constructs in 
Educational Diagnosis and Evaluation (Green, n.d.).  This is broken down into the first three 
phases of the model including diagnosis of the social problem that is affecting the quality of life 
of the population of interest, the epidemiological diagnosis that determines the specific health 
issues of the community followed by the education diagnosis that identifies interventions that 
applies to the patient population selected (Green, n.d.).  PROCEED is the second acronym that 
stands for Policy, Regulatory, and Organizational Constructs in Educational and Environmental 
Development (Green, n. d.).  The remaining five phases, including organizational policy 
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development, implementation of the program, process evaluation, impact evaluation, and finally, 
outcome evaluation for the implemented policy to address the identified concern, make this 
model applicable to the DNP project to implement a new policy.     
The PRECEDE-PROCEED model application to the community health setting, followed 
by public health interventions focus on interventions to improve overall health.  As it applies to 
the co-prescribing naloxone policy, it will be used to reduce harm in the community. 
Application to practice change.  The PRECEDE-PROCEED Model is an evidence-
based model that will help guide the implementation of the policy to co-prescribe naloxone for 
the chronic pain population receiving opioid therapy.   There are nine stages to the PRECEDE-
PROCEED Model for healthcare policy implementation.  The opioid epidemic and high rate of 
overdoses are a community-wide issue; identifying the social diagnosis is stage one of the model.   
The desired outcome is identified to reduce the amount of opioid-related overdose deaths.  This 
goal identified in Healthy People 2020 and harm reduction in the patient population under the 
care of a provider for pain with opioid medications.    
The second stage of the model is the epidemiological diagnosis, identifying the people at 
risk for opioid overdose and whom it effects.  The chronic pain patient population that is treated 
with opioid medication is at risk for opioid overdose or death by taking a high-risk medication to 
treat chronic pain.   The third phase is the behavioral diagnosis, patients on chronic opioid 
therapy once again are the targets for an improvement in patient outcomes, and chronic opioid 
medication use predisposes patients to an opioid-related overdose. It essentially enables family 
and friends access to opioid medications.   
The fourth and fifth phases of the PRECEDE-PROCEED Model are the developing and 
implementation of a healthcare policy to address the healthcare need and improve the quality of 
CO-PRESCRIBING NALOXONE POLICY 32 
life for this patient population identified.   The educational component of a healthcare policy is 
evaluated in this phase.  For this DNP project, there was a specific lack of provider education 
regarding the prescribing of naloxone that has been identified.  A second educational opportunity 
is the patient education for when the appropriate administration of the naloxone should be done.  
Therefore, the co-prescribing naloxone policy addresses both of the education opportunities and 
was an essential component of the healthcare policy for co-prescribing naloxone.   
The sixth phase of the model is the actual implementation of the policy to the specific 
patient population identified; chronic pain patients treated with opioid medications.  After 
implementation of the policy, phases seven and eight address progress assessment and impact 
assessment.  The nursing staff will address progress assessment with a patient survey at the end 
of each patient visit, just prior to discharge once the policy is in place.  The survey questions will 
specifically address any lack of adherence for the providers and nursing staff throughout the 
project on a weekly basis.  This will guide the DNP project manager in any changes that need to 
be made in the implementation process or if further guidance is needed.  The impact assessment, 
phase 8, will also utilize the same patient survey information and data collected throughout the 
implementation process.  The overall impact of the policy for co-prescribing naloxone will be a 
collection of this same information over a longer period of time.  
The final phase of the model is the results of the policy implementation.  At this point the 
final phase and evaluation will reveal if the policy improved patient outcomes by decreasing risk 
factors for patients treated with opioid medications for chronic pain.   The PRECEDE-
PROCEED model is logical to follow for policy implementation and evaluation to improve 
patient outcomes in this patient population (see Appendix I).   
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Summary  
 Pender's health promotion model is grounded in identifying the significant factors 
influencing health behavior and health promotion.  This model also identifies a component in 
health promotion that is influenced by the social and cultural environment for a patient that 
impacts health.  The health promotion model is essential to understand that the opioid crisis is a 
community-wide problem and the importance of co-prescribing naloxone to patients in the 
chronic pain population.  Improving and influencing health-promoting behavior can be done by 
family, peers, and health care providers, and for this reason, Pender's theory applies to this DNP 
project. 
  To implement the naloxone co-prescribing policy, the PRECEDE-PROCEED model 
outlines a model that will encourage the success of the policy by identifying the problem and 
essentially working backward to finding a solution.  The number of opioid-related overdose 
deaths is the problem identified for health promotion in the chronic pain population.  All phases 
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Chapter Four:  Pre-implementation Plan 
Policy implementation takes planning, and a good implementation plan has the potential 
to improve outcome measures for a DNP project.  The opioid crisis has shed light on the 
increasing number of opioid-related overdose deaths.   A policy applying the universal 
precautions model to co-prescribe naloxone to all patients receiving an opioid medication can 
decrease the chances of an opioid-related death for this patient population and remove the stress 
of risk stratification for providers.  The organization did not have a policy previously in place to 
address prescribing naloxone to patients who may or may not display risk factors for opioid-
related overdose.  The implementation of a successful policy will take collaboration with the 
providers and nursing staff to ensure policy compliance.  The private practice and site for this 
quality improvement DNP project is willing for this policy implementation and tracking the 
improvement in patient outcomes and in community health. 
Project Purpose 
 The purpose of the DNP project is to decrease opioid-related overdose deaths in the 
chronic pain population receiving a prescription for an opioid medication. Healthy People 2020 
identifies opioid-related overdose deaths as a focused objective related to substance abuse.  
Decreasing opioid-related over-dose deaths will address the Triple Aim in healthcare by 
improving patient care health by decreasing the risk of an adverse outcome with an opioid 
medication, reducing cost in emergency room visits.  Therefore, reduction of overall cost of care, 
and improving patient education regarding medications.   Partnering with a pain clinic to 
implement a clinic policy to co-prescribe naloxone to each patient receiving an opioid 
prescription can impact this patient population by increasing patient safety and decreasing 
adverse outcomes (see Appendix H).   
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Project Management 
Organizational readiness for change.  The organization, a private pain clinic in Eastern 
NC, does not currently have a policy regarding naloxone in place to address this critical 
component of taking care of chronic pain patients maintained on opioid medications.  Prescribing 
naloxone to all patients receiving opioids as a treatment for chronic pain is the missing 
component.  Currently, a naloxone prescription is not consistent practice, and for the most part, 
is based only on the individual patient risk factors.  At previous staff meetings, the nurses have 
expressed concern for the lack of consistency with the prescribing of naloxone between 
providers.  The most significant barrier, as with any new policy, can be adherence by the 
providers and nursing staff.  Potentially, the time constraints for patient education regarding the 
naloxone can impact policy implementation.  However, as a project leader, it is essential to 
address this potential barrier by streamlining patient education in a pre-made packet to be as 
efficient as possible.  Optimizing education has the potential to improve adherence to the policy 
for the nurses providing naloxone education to the patients and is a critical component to the 
policy’s success.  Although patient education is an additional task for the nursing staff, there is 
significant interest in improving the consistency of prescribing naloxone to all patients.   
Interprofessional collaboration. For the policy implementation to be successful, it will 
take the cooperation of the project site champion, DNP project lead, the office manager, the 
providers, and the nursing staff of the pain clinic.  As the DNP project lead, it will be essential to 
coordinate meetings for staff education and set forth a clear implementation timeline with the 
office manager.  The site champion will be instrumental in supporting the implementation of the 
policy with the provider adherence.  It will also be beneficial in reviewing the process throughout 
the implementation to determine if additional education is required for the providers or nursing 
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staff.  The nursing staff will be instrumental in the patient education component of policy 
implementation.  The perception is that the DNP project lead is the top of the hierarchy; 
however, collaboration is more critical to accomplishing successful policy implementation. 
Risk management assessment. The strengths, weaknesses, opportunities, and threats of 
a project, known as SWOT analysis, can evaluate a project for potential issues during the 
implementation process.  The strengths of this project include the implementation of a policy to 
the clinic where one does not currently exist.   The policy implementation can be done once the 
provider and nursing education is complete.   Provider and nursing education that takes place 
before implementation can make this a smooth transition into a practice change for the providers 
and solve questions, concerns, and provide clarification for the staff prior to implementation.  
The policy implementation date will be determined and from there, the policy can be expected to 
be followed by all of the staff for the clinic site.    
Weaknesses for the policy implementation include the time-consuming nature of the 
patient education for nursing that is a component of successful policy implementation.  Patient 
education for the nursing staff to complete at discharge will be a packet of three to four 
documents to be reviewed with the patient.   The post-policy implementation survey will be less 
time consuming than the primary education, taking five minutes or less.    
The clinic site presents an excellent opportunity to improve patient outcomes with a 
naloxone policy implementation and dissemination in the future to the other clinical sites in 
practice throughout NC.  Currently, there is not a policy in place for any of the clinical sites of 
this practice.  The project is an opportunity to address a Healthy People 2020 goal to decrease 
opioid-related deaths, improving patient safety, reducing adverse outcomes, and addressing a 
community health issue for the patient pain population.    
CO-PRESCRIBING NALOXONE POLICY 37 
Threats to the co-prescribing naloxone policy include provider compliance.  Compliance 
can be at the provider level or the nursing level, and include the potential of not prescribing the 






















Figure 4.1.  SWOT Diagram for Co-Prescribing Naloxone Policy Implementation 
 
Organizational approval process. The organization is an extensive anesthesia practice 
across NC with a pain management division under the larger entity.  The eastern NC pain clinic 
site is private practice.  Concerns presented by the nursing staff have been due to the lack of 
consistency of prescribing naloxone between the providers.   For this reason, a meeting 
scheduled with the medical director was an opportunity to present the proposed DNP project.  
The project approval was seamless after the concern and recognition that a policy was not in 
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champion, office manager, and DNP project lead outlining the proposed DNP project process 
and potential outcome measures.  The literature review was helpful to support the co-prescribing 
naloxone policy, and the site approval letter from the practice manager was provided to proceed 
with the implementation of the policy.  The clearance site letter was completed by the end of the 
week to pursue the project at this site.  Due to the opioid epidemic, this project is focusing on 
harm reduction. The practice agreed to provide this author the pain clinic to pursue the DNP 
proposed project (see Appendix C).    
Information technology. The information technology of this project is minimal since it 
involves a policy implementation.  Information that relates to the policy, including the patient 
education, will be a part of the electronic health record (EHR) as a document in the media tab via 
scanning into the chart.  The EHR will not be used to collect any data for this project.  An Excel 
spreadsheet will be used to track the data collection from the post-implementation policy survey 
that will be administered by the nursing staff; however, it will not include any patient 
information. Provider and nursing education will be a presentation in a PowerPoint format with a 
printout of the presentation slides.   
Cost Analysis of Materials Needed for Project 
 The cost burden of opioid-related overdose deaths is an economic burden on health, 
substance abuse, and the criminal justice system that totals close to $79 billion, according to the  
Center for Disease Control and Prevention (2016).  There is an average of $15,000 cost 
difference for patients that carry a diagnosis of substance abuse or opioid dependence according 
to 2013 data from the National Center for Injury Prevention and Control (Florance, Lu, Xu, & 
Zhou, 2016).  This is a significant health care cost burden for the nation.  The cost associated 
with providing a prescription for naloxone and education is minimal in comparison.   
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 The Federal Drug Administration (FDA) reveals that naloxone can cost from $150 to 
over $4000, depending on the administration route, intravenous, subcutaneous, or intramuscular 
(Jiang, 2018).  In comparison, the wholesale generic cost of naloxone is $20, and in comparison 
Evzio, the brand name autoinjector is $4000 per dose, a 680 percent increase in cost (Wood, 
2018).   In this project, each patient education packet costs less than $10; this includes a magnet 
for the refrigerator to indicate to emergency services, family, or friends where naloxone is 
located in the home.  The education for the providers and nursing is minimal in cost, other than 
the cost of their time (see Appendix D).   
 A prescription for naloxone and patient education can decrease healthcare costs 
additionally in emergency room visits. It is difficult to evaluate a specific value due to the 
difficulty of tracking whom the naloxone had been prescribed to, and who administered or 
received the medication.  Regardless of whom the medication is used on, it will decrease 
healthcare costs and potentially identify those who may need further substance abuse counseling.   
Plans for Institutional Review Board Approval 
 This project site does not have an independent Institutional Review Board (IRB).  The 
practice does not have a formal process for project approval. This will be the first formal quality 
improvement project performed at this practice site. The process for site approval was a 
presentation to the medical director, identifying the need for a policy, and the practice benefits 
regarding patient outcomes accomplished in a 45-minute meeting.  The project idea was 
introduced to the practice manager, and site champion, with a presentation outlining the project 
and the site clearance approval letter then followed.     
For the East Carolina University IRB process, initially, an IRB QI/program evaluation 
self-certification tool was completed that included eight questions regarding the project, and a 
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brief description.  The DNP faculty, fulfilling the initial stage of the IRB evaluation process, 
approved the initial self-evaluation. The second stage of the process was submitted via a 
Qualtrics™ survey.  Upon submission, the project was deemed quality improvement, and did not 
require IRB approval  (see Appendix D).  
Plan for Project Evaluation 
Demographics. The data collection will be accomplished with a patient survey to be 
administered by the nursing staff (see Appendix F).  The demographic information collected will 
be limited to age, gender, and education level.  The demographic variables for age will be 
demonstrating ranges in a circle graph.  Gender will be reported in percentage distribution.   The 
education level and distribution will be presented in a bar graph.   
Outcome measurement. The primary outcome for the project is an increase in co-
prescribing naloxone with any opioid medication to patients in treatment for chronic pain.  
Ultimately, the increase in the availability of naloxone will decrease the risk of opioid-related 
overdose deaths for the chronic pain patient population.  The outcome measures will be derived 
from the post-policy implantation survey.  The patient survey will include the three questions 
addressing naloxone patient education, rendering the naloxone prescription, and filling the 
prescription for naloxone (see Appendix F).    
If the naloxone is not co-prescribed by the provider, there may be an indication that more 
provider education is needed.  Policy adherence is an outcome measure.  If the naloxone is 
prescribed, and patient education is not provided, the patient may not understand when or how to 
administer the life-saving medication. Therefore, it does not matter that the prescription was 
provided to the patient.  Further education will be needed for the nursing staff regarding the 
importance of patient education.   
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Lack of patient education could result in poor patient outcomes, and the decrease in 
opioid-related overdose deaths may not improve.  This outcome is a process measure that can be 
impacted by patient education and the overall patient outcome.  Tracking distribution of patient 
education packets will indicate if further nursing education is essential.  
Finally, the last question indicates ultimately that the patient understood the prescription 
for naloxone was rendered, and that patient education was received, including the importance of 
having this medication available.   Filling the prescription is the final step to impact safety and 
positively impact patient outcomes when taking opioid medications for chronic pain.  The three 
outcome measures include a process measure, an outcome measure, and lastly, a clinic measure.  
The overall goal is to improve patient outcomes, and if the naloxone is not filled, this will never 
improve.   
Evaluation tool.  The evaluation tool used for this DNP project is a patient survey that 
the nursing staff administers on a follow-up visit prior to discharge.  The survey will consist of 
six questions, three demographic questions, and three outcome measure questions after the policy 
implementation.  The creation of the patient survey is specific to this DNP project. Therefore, 
permission to use the tool is not necessary (see Appendix F). 
Data analysis.  The data from the evaluation tool will track with an Excel spreadsheet.  
The outcome measures are binary, meaning the outcome measures have been met or not since the 
project will implement a new prescribing policy.  Data will be collected each night from the 
nursing staff at the clinic to be entered into the spreadsheet three times a week.   
The primary outcome measure will determine if the providers are abiding by the policy. 
As the data is collected, there may be an identified need for an increase in provider or staff 
education.   
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The second measure is process measure analyzing if the nursing education is provided; if 
nursing does not follow this process, the outcomes will not be accomplished.  Therefore, as the 
data is entered, and analysis starts, this can indicate if more nursing education is needed to 
impact better results.   
Finally, the third outcome measure is determining if the patient filled the prescription for 
the naloxone; this is the ultimate project outcome, and may be impacted by the process.  For this 
reason, it is essential to start data analysis and measures frequently and consistently throughout 
implementation to make adjustments and potentially improve patient outcome measures.  There 
are currently no benchmarks to use for comparison.    
Data management. Project data collection will be each evening after the clinic is 
complete.  On Mondays, Wednesdays, and Fridays, the patient surveys will be coded and entered 
into the Excel Spreadsheet.  Frequent data entry will ensure adequate time to make any 
adjustments to the policy the next week, including the additional provider or nursing education.  
The paper surveys will be collected at patient discharge and stored in a locked file cabinet in the 
office manager’s office for the duration of the project.  The information is then collated in the 
Excel data spreadsheet for data analysis on a password-protected computer; however, the hard 
copy of the survey will be accessible if needed throughout the project duration.  Once the project 
is complete, the patient surveys will be shred, and the Excel spreadsheet will be kept for later 
dissemination and poster information. There will not be any patient information included in the 
survey information.  The practice administrator, project site champion, office manager, and 
project leader will have access to the information collected for the project. 
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Summary 
 The DNP project site is ready for change and improvement in practice.  Although, in this 
practice, naloxone prescribing is addressed for high-risk patients, there is not currently a policy 
in place to ensure consistency.  Readiness for change will enhance provider compliance, and in 
combination with nursing education prior to policy implementation, there is an expectation for 
improving patient outcomes.  Data collection with a patient survey will provide outcome 
measures throughout the implementation process to continuously evaluate provider and nursing 
compliance.  This will allow the project to evolve to accomplish measurable outcomes including 
prescribing naloxone, patient education for how and when to use the medication, and finally 
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Chapter Five:  Implementation Process 
Policy implementation takes organization from the project leader and cooperation from a 
clinical site that is willing to change.  A private practice pain clinic that is a part of an extensive 
anesthesia practice has identified a need for practice change to decrease the risk of opioid-related 
overdose deaths for patients receiving opioid medications.  The project will include all six 
providers in the practice, and the three nurses in the practice location. The policy will apply to 
the entire clinic.  The PRECEDE-PROCEED model will guide the policy implementation and 
the potential need to modify the implementation throughout the process. 
Setting 
        The setting for this DNP project is a private practice office-based setting.  The private 
practice is an extensive anesthesia practice located across the state of North Carolina (NC).  
Within the anesthesia practice, there is a pain management division.  The project site is the office 
in eastern NC that is a part of the pain management division of the larger anesthesia practice.   
The practice does affiliate with the local medical center regarding anesthesia; however, the pain 
division is only private practice.  The majority of the patient population in the DNP practice site 
has commercial insurance. 
Participants 
        The DNP project participants are the provider and nursing staff for practice location.  There 
are four physicians, two nurse practitioners, and three nurses that will be participating in the 
policy implementation.  Three of the four physicians are anesthesiologists and board-certified in 
pain management. The remaining physician is specialized in physical medicine and rehabilitation 
and is also board certified in pain management.  The physical medicine and rehabilitation 
physician is the site champion for the DNP project.   
CO-PRESCRIBING NALOXONE POLICY 45 
 In addition to the providers and nursing staff, the office manager will also be helpful in 
the policy implementation in staff education and day-to-day evaluation to ensure the 
implementation is progressing smoothly.  The practice office manager will be essential in 
helping identify any issues or changes that need to be addressed during the implementation 
process to ensure the success of the policy.  All of the participants are employees of the more 
extensive anesthesia practice, the nursing staff have been working full time in this location, and 
the providers rotate to three of the other pain management clinics in practice. 
Recruitment 
        The participants of this DNP project came to be as an employee of the practice at the 
specific clinical site on a regular basis.  Those providers and nurses not employed at the project 
site are not to be included in the co-prescribing naloxone policy implementation.  Before the 
policy implementation, the providers will participate in a staff meeting to include policy 
education and the implementation process for the clinic location.   Each provider and nurse will 
be made aware of the specific implementation date for the policy, and after that, assume to abide 
by the co-prescribing naloxone policy.  This education will also include a PowerPoint for the 
policy and additional information.  
          The participants are a convenience sample based on the assumption that they are required 
to participate as employees of the practice.  The option to not participate has been given to the 
employees.  The participant groups are providers, nursing staff, and ancillary staff.  The job roles 
identify the subgroups, and each will be engaging in a different aspect of the project 
implementation.  The provider group has an interest in engaging in the project to provide 
consistency in care to the patients that are on chronic opioid therapy.  The nursing staff has a 
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desire to create a standard of care for the clinic for all patients that receive opioid medication to 
chronic pain patients.   
          Prior to the policy implementation, a staff meeting addressed the provider and nursing 
education; there was a sense of excitement and relief with the staff to create a new standard of 
care.  The consistency with a new policy in the clinic has the potential to improve patient 
outcomes and decreases the risk of adverse patient outcomes for the chronic pain population.  
The chronic pain population is a high-risk patient population for opioid-related overdose deaths. 
The providers and nursing staff are receptive to any change to improve patient outcomes.  The 
most prominent concern after the provider education time was the patient cost of the naloxone.  
The cost of the medication is dependent on insurance coverage, although NC does allow patients 
to pay for naloxone over the counter without the use of insurance. 
Implementation Process  
          The PRECEDE-PROCEED model will guide the policy implementation process  (see 
Appendix I).  The initial stage, known as social diagnosis, begins with the identification of the 
opioid-related death risk factor for patients on chronic opioid therapy.  Although the DNP project 
site providers do prescribe naloxone, it is not consistent among the providers, and therefore 
identified a need for a policy.. The creation of the policy is the second and third stages of the 
PRECEDE-PROCEED model. The co-prescribing naloxone policy need was identified based on 
the opioid epidemic that has been identified by the CDC.   
The fourth stage of the PRECEDE-PROCEED model is the educational component of 
policy implementation.  The next step was to identify the materials for the patient population 
regarding naloxone education and use. A patient information packet was created, including 
information about naloxone, when and how to use opioid medication safety, where to keep 
CO-PRESCRIBING NALOXONE POLICY 47 
opioid medications, and the risk factors when taking opioid medications. The patient education 
packet includes a magnet for the patient to place on the refrigerator to identify the naloxone 
location in an emergency.   The magnet potentially would be for any family member or first 
responder that enters the home in an emergent situation to be able to locate the naloxone.   
The policy is the fifth stage of the PRECEDE-PROCEED model.   The fifth stage is 
developing a policy to address the community health assessment issue.  A policy can then 
address the identified social and environmental factors in the community.  The need for patient 
education materials is identified as specific to the opioid-related overdose risks. At that time, a 
policy is written for the practice location utilizing the universal precautions model from 
infectious disease and Pender’s health promotion model.  The goal is to prescribe naloxone to 
every patient receiving opioid medication for chronic pain regardless of individual risk factors 
(see Appendix C). 
The implementation of the policy is the next step, and also stage six of the model.  Before 
the implementation of the policy, provider education regarding the policy is accomplished in a 
staff meeting utilizing a PowerPoint presentation. The PowerPoint includes the actual policy, 
why the policy is essential with supporting evidence, the overall goal of implementation, and 
how to accomplish the policy change within the clinic site. The nurses will be included in 
education due to the essential role they will play in patient education. After the instruction is 
complete, a policy implementation date of January 13, 2020, is set. 
The evaluation of the project during the implementation process is known as progress 
assessment, or stage seven of the PRECEDE-PROCEED model.  Once the policy is in place, the 
nursing staff will identify any patient receiving an opioid medication before discharge. The nurse 
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will present the education packet to the patient, and record the packet number, and if the nurse 
provides the naloxone education. If the education was not provided, documentation would be 
recorded in the log. This log will be later recorded into an Excel spreadsheet at the end of each 
day.  
Stage seven of the PRECEDE-PROCEED model is defined as impact assessment.  One 
month after the policy implementation, the nursing staff administered a post-implementation 
survey to all patients receiving an opioid medication. The post-policy implementation survey 
consists of six questions for every patient, including if naloxone education was completed, if a 
prescription for naloxone was rendered, and if the medication was filled.  There are additional 
three demographic questions that will be included.  The administration of the survey will be in 
addition to continuing to identify patients needing a naloxone education packet.  
This final data collection is the eighth and final stage of the PRECEDE-PROCEED 
model known as results assessment.  Once the nurse completes the short questionnaire, it will be 
placed in a locked cabinet and recorded in the Excel spreadsheet each week. The data will be 
kept weekly in the spreadsheet, as well as the totals for all of the data collected.  The hard copies 
of the survey will be kept for the duration of the project and then destroyed. The data collection 
will take place for approximately 90 days.   
Plan Variation The PRECEDE-PROCEED model is a guide for healthcare policy 
implementation and revision during the implementation process.  Throughout implementation, 
the project was able to continue.  However, the data collection at the clinic site was impacted by 
the COVID 19 health pandemic that was named by the CDC on March 10, 2020.  Many of the 
patients face to face clinic visits were transitioned to a telehealth visit utilizing a platform called 
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Doxy.me.  The patients presented virtually, therefore, were not physically present in the clinic to 
collect the post-implementation survey information.  At this time, a decision was made with the 
site champion to continue data collection over the phone when appropriate by the provider or 
nursing staff.  At this time, a practice decision was made not to initiate any opioid medications 
without a face to face visit. Therefore, the number of opioid packets dispensed to patients 
significantly decreased since March.    
Summary 
        For policy implementation to be successful, an organized implementation plan is a 
necessity.  The PRECEDE-PROCEED model is a guide for policy implementation that is 
beneficial for the process, including process evaluation throughout the implementation before the 
final stages of impact and results assessment.  The goal of policy implementation is to improve 
an identified community or environment that describes a social diagnosis to improve a specific 
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Chapter Six:  Evaluation of the Practice Change Initiative 
The co-prescribing Naloxone to Chronic Pain Patients receiving Opioid Therapy Policy 
implementation revealed short and long-term goals that can be objectively measured with the 
results of a patient survey administered by the nursing staff at the DNP project site.  The data 
gathered was straight forward, and due to the project being a policy implementation, the results 
included are throughout the implementation time frame.  There is no data to compare from 
before the policy implementation. The project did reveal intended and unintended outcomes that 
had not been identified before implementation, affecting the number of surveys administered in 
the implementation process and an unexpected health pandemic. 
Participant Demographics 
           There was a total of 48 total DNP Project participants in the post-policy implementation 
survey data collected by nursing staff (see Appendix G).  The participants were comprised of 
52% males and 46% females, leaving 1% of the participants who preferred not to answer the 
question.   Forty-six percent of the patients were of the ages 51-60  (see figure 6.1). 
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          The education level of the DNP project participants varied from some high school to 
graduate degree. However, 46% of the participants had completed some college.  Thirty-one 
percent of the remaining patients had completed a college or graduate degree, while 17% of the 
participants graduated from high school.  Six percent of the participants had not completed a 
high school degree (see Figure 6.2).   
 
 
Figure 6.2. Education level of the project participants.   
 
Intended Outcome(s)  
Short-term outcomes. The short-term outcomes of this DNP project include the 
implementation of the co-prescribing naloxone policy.  A component of the policy 
implementation was to provide each patient with an opioid packet that is receiving an opioid 
medication.  This opioid packet includes education materials for opioid medications, naloxone 
education, instructions for the use of the rescue medication, a prescription for naloxone, as well 
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percent of the patients at the project site have been provided an opioid packet and education 
when prescribed medication for chronic pain.   
Intermediate Outcome. An intermediate outcome in this DNP Project was to determine 
if a prescription for naloxone was provided to every patient receiving an opioid medication for 
chronic pain.  Fifty-eight percent of the patients at the DNP project site have been provided a 
prescription for naloxone.   
Long-term outcomes.  Long term outcomes include increasing the consistency of the 
providers prescribing naloxone to chronic pain patients on opioid therapy.  A second long term 
outcome evaluated in this DNP project policy implementation included filling the naloxone 
prescription that was rendered to the patient after the policy implementation.  
   Findings. The post-policy implementation survey revealed that 77% of the patients 
received an opioid packet. Fifty-eight percent of the patient population revealed in the survey 
that a prescription was rendered at the time of the visit.  In contrast, the remaining 33% of the 
patients did not receive an opioid packet with education, and 42% did not receive a naloxone 
prescription at the time of their visit.  Provider and staff education potentially could improve this 
finding to the goal of 100% adherence to the policy (see Figure 6.3).   
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Figure 6.3.  Percentage of patients that received an opioid packet and naloxone education.   
Although the patients were educated about the risks of chronic opioid therapy, only 33% 
of the patients filled the naloxone prescription, and 54 % chose not to fill the prescription.  
Thirteen percent of the patients stated that the prescription for naloxone remained at the 
pharmacy, and had not picked up at the time of the survey, although it does not identify why the 
prescription was not filled (see Figure 6.4).     
 
 
Figure 6.4.  Number of project participants that filled the naloxone prescription that rendered at 
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An unintended consequence of this DNP project was the actual number of patients 
prescribed schedule II narcotics at this practice site was lower than expected. The Drug 
Enforcement Agency (DEA) schedules medications into five categories depending upon the 
acceptable medical use of the medication as well as the abuse and dependency potential (United 
States Department of Justice [USDJ], n. d.).  Schedule I medications have a high level of abuse 
potential and physical dependence, as the schedules decrease, so does the abuse and dependence 
risk for the medications, some examples include buprenorphine products or tramadol (USDJ, n. 
d.).  Schedule III medications contain less than 90 milligrams of codeine per unit or dose per the 
DEA (n.d.).  In comparison, schedule II medications are the more potent opioid medications 
including medications such as hydrocodone, oxycodone morphine, etc. with higher abuse 
potential and physical dependence (USDJ, n. d.).  The number of surveys collected was lower 
than expected.  The project site does have a significantly higher proportion of patients taking 
schedule III medications with opioid properties, including tramadol and buprenorphine products.  
If patients receiving schedule III drugs were included in the data collection, the findings would 
include a larger sample size.   
A second unintended consequence of the DNP project was the public health pandemic 
that occurred during policy implementation.   On March 10, 2020, the World Health 
Organization declared the COVID-19 viral disease to be a pandemic.  As a result of this 
emergency, practice patterns were shifting to accommodate the need to treat with unprecedented 
guidance from federal, state, and local authorities.  Some of the advice included, however, was 
not limited to self-quarantine and limiting physical proximity to others.  Patient care continued 
with the utilization of "telehealth" visits rather than a face to face visits.  For this reason, during 
the implementation, adjustments were made in how the survey was administered.  Initially, the 
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nursing staff administered the survey prior to the patient's discharge.  During the health 
pandemic, telephone surveying was used to administer the remaining surveys for the 
implementation period. 
Summary 
 The DNP project policy implementation and data did reveal a discrepancy when 
comparing the number of opioid packets provided to patients and the number of naloxone 
prescriptions rendered.  If providers had followed the policy, 100% of the patients should have 
received an opioid education packet and a naloxone prescription.  However, in comparison, only 
77% of the patient received an education packet and subsequently, 58% of the patients received a 
prescription for naloxone.  Provider adherence to the policy was a significant factor in the 
discrepancy.    
 After the policy implementation, only 33% of the patients filled the naloxone 
prescription.  Risk mitigation for the chronic opioid patient was removed using the universal 
precautions model; however, patients still did not recognize the importance of filling the 
naloxone prescription and the risk of chronic opioid medication usage.  A consideration in the 
future to combat the patient lack of adherence to medical advice will be to discontinue the use of 
an opioid medication if the prescription is not filled to guarantee the availability of naloxone to 
this high-risk patient population.   
 The unintended consequences did affect the number of surveys collected for the 
implementation period and an unexpected health pandemic.  Change in practice did affect survey 
collection and the number of patients available for this DNP project.  Although only 33% of the 
patients included in the survey filled the naloxone prescription, there will still be a positive 
impact on harm reduction in the chronic pain patient population.      
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Chapter Seven: Implications for Nursing Practice 
The eight DNP essentials create the foundation of the doctorate of nursing practice 
degree.  This DNP project is a quality improvement (QI) project using a policy implementation 
to fulfill all eight of the essentials to advance nursing practice.  Advancing nursing practice in the 
future with the dissemination of the data collected to improve patient outcomes and harm 
reduction to a broader patient population is the ultimate goal.  Dissemination of the data includes 
potentially applying the policy to future nursing and standard of care practice. 
Practice Implications 
             Essential I: Scientific underpinnings for practice.   The scientific underpinnings for 
practice are grounded in evidence-based research and the practice of nursing, specifically chronic 
pain management.  The CDC has outlined guidelines and recommendations for prescribing 
opioid medications due to the opioid crisis in the community.  The literature review reveals 
evidence to support the prescribing of naloxone for harm reduction in this patient population.  
The literature review indicates that risk analysis is a difficult task for providers in the chronic 
pain population and has been a barrier to prescribing in the past.  In this DNP project and policy 
implementation, practice guidelines have the potential to impact harm reduction by removing the 
task of risk assessment and prescribing naloxone to each patient receiving a prescription for a 
schedule II opioid to treat chronic pain utilizing the universal precautions model from infectious 
disease, and Pender’s health promotion model.   
 Essential II: Organization and systems leadership for quality improvement and 
systems thinking. There is an opportunity for quality improvement when there is an identified 
community health crisis.  For this DNP project, the opioid crisis provides an opportunity for 
harm reduction and quality improvement.  As an advanced practice nurse, this crisis provides an 
CO-PRESCRIBING NALOXONE POLICY 57 
opportunity to implement a quality improvement project to fulfill Essential II.  The co-
prescribing Naloxone policy in this DNP project is an example of identifying a health crisis, and 
attempting to improve harm reduction and patient outcomes through prescribing naloxone to all 
patients receiving a schedule II opioid prescription independent of risk factors. Accomplishing 
harm reduction for a specific patient population helps advance the practice of nursing for current 
and future nurses.   
  This DNP QI project policy will be utilized initially in one practice site. The intention is 
to disseminate the information throughout the practice to all clinic sites managing patients with 
chronic pain, and further dissemination potentially to all the clinical sites across the state of NC.      
 Essential III: Clinical Scholarship and analytical methods for EBP.  A literature 
review provided the foundation for this DNP project policy development.  Evidence-based 
practice literature for the chronic pain population includes retrospective studies on the chronic 
pain population and data for naloxone prescriptions rendered by the provider in the current health 
care setting.  The literature review also revealed the barriers to prescribing that included the 
provider burden of risk evaluation.   Risk evaluation is difficult to access for many reasons, 
including provider apprehension, lack of time, and the honesty of the patient on the first visit 
without a patient-provider relationship established.  These examples demonstrate the benefit of 
omitting risk evaluation in many clinical settings.  Application of the universal precautions 
model to the chronic pain patient population on opioid therapy removes the stress of risk 
evaluation for providers.  The knowledge gained through the literature review is beneficial to 
develop the Co-prescribing Naloxone Policy for implementation in the chronic pain population 
for harm reduction.    A PowerPoint presentation accomplished the nursing staff, and provider 
education for policy implementation in a clinical meeting setting.  Throughout implementation, 
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the nurses collected data that is presented in an Excel spreadsheet that reflects total data collected 
and then broken down into weekly data collection segments.  Throughout the project 
implementation, other platforms including electronic mail, telephone calls, and face to face visits 
for communication. 
             Essential IV: Information systems/technology and patient care technology for the 
improvement and transformation of healthcare.  Information systems that including the 
Laupus Library one bar search engine were used for the literature search, providing access to 
many resources through technology.  During project implementation, and data collection, Excel 
spreadsheets are beneficial to organize and keep track of the data collected.  The Excel 
spreadsheet will allow data collection presentation in the future, including graphs, charts, and 
create visuals for a PowerPoint poster presentation.  This technology will facilitate the 
dissemination of the data for future improvement in health care policy for naloxone, and 
continue harm reduction. 
             Essential V: Healthcare policy for advocacy in healthcare. Healthcare policy is a 
strategy to advocate safer practice and improve patient outcomes in healthcare based on literature 
review and research.  This DNP project is a policy implementation that advocates for harm 
reduction in the chronic pain patient population.  The foundation for the policy is grounded in the 
Essentials I and III through research and evidence-based practice.  Literature supports that 
patients provided with chronic opioid therapy are at increased risk for overdose.  One of the only 
ways to accomplish harm reduction in the chronic pain patient population is to provide patients 
with a prescription for naloxone, and education on how or when to utilize the medication.   
             Essential VI: Interprofessional collaboration for improving patient and population 
health outcomes. Interprofessional collaboration is essential for improving patient and 
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population health outcomes.  Collaboration with physicians, nursing staff, and pharmacies, to 
name a few are essential to improve patient outcomes.  For example, the knowledge of the site 
champion, the ability of the nursing staff to provide patient education, and the pharmacy helping 
the patient being able to fill the naloxone prescription written by the provider are all essential for 
the policy to be successful.  The interprofessional collaboration will support successful policy 
implementation.   The interprofessional collaboration will potentially enhance future 
collaboration with other practice sites as well. 
             Essential VII: Clinical prevention and population health for improving the nation’s 
health. The opioid crisis has highlighted the risk of overdose death in the US.  This DNP project 
policy potentially will prevent or decrease the number of opioid-related overdose deaths, and 
reduce harm in this patient population.  The data collected has the potential to support this DNP 
project policy to be utilized in many health care settings, including specialty, and primary care 
clinics. 
             Essential VIII: Advanced nursing practice. Advanced nursing practice is using 
underlying knowledge and scientific underpinnings to apply to a current health crisis or problem 
to improve patient outcomes and the population.   This DNP policy implementation project is 
grounded in the literature review, scholarship, collaboration, data collection, and presentation to 
advance nursing practice.  The first seven Essentials culminate to fulfill the eighth Essential and 
advance the practice of nursing through quality improvement to disseminate to a broader patient 
population.    
Summary  
        The eight DNP Essentials are the building block for the Doctoral Education for Advanced 
Nursing Practice.  Each Essential provides a greater depth of knowledge to pursue a successful 
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project, collaboration, and dissemination to complete the requirements for the DNP degree to be 
completed and, ultimately, advanced nursing practice.  The eight DNP Essentials have been met 
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Chapter Eight: Final Conclusions 
Quality improvement projects are essential to improve patient care and outcomes, and 
policy implementation is a way to accomplish a specific patient population.  This DNP quality 
improvement project addresses potential patient harm for the chronic pain population on opioid 
therapy.   
Significance of Findings  
           The post-policy implementation survey found that 77% of the patients received an opioid 
packet and naloxone education; the goal or intention of the policy was 100%.  The same patient 
population participating in the survey revealed that only 58% of the patients received a naloxone 
prescription at the time of the visit.  Provider adherence to the policy had a significant impact on 
the findings.  The outcomes of the project intended to improve the consistency of co-prescribing 
naloxone with opioid medications, increase patient knowledge and naloxone prescription filled 
by the patient.  One third of the patients that did fill the prescription have the potential to 
decrease harm.   However, moving forward provider and staff education for the policy will need 
to be reinforced for improved adherence.  Before the organization policy implementation in the 
other clinic locations, staff education needs to be more intensive and consistent for better 
adherence.   Information that would be beneficial regarding the next step would include 
identifying the barriers to filling the naloxone prescription.  An example may be the cost of the 
naloxone that may be a barrier for patients.  Out of pocket cost for the naloxone or lack of 
understanding of the purpose of the naloxone are examples of barriers for the patient filling the 
naloxone.  The over-the-counter cost for naloxone is $40.   
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Project Strengths and Weaknesses 
          Strengths.  The strengths of the project include the simplicity of policy implementation 
and the minimal cost to the organization.  The PRECEDE-PROCEED model outlines an 
organized process for the implementation of a health care policy and periodic review to ensure 
success.  The education material is reproduced at a low cost per patient and can be adjusted 
depending on the organization’s needs.  A regular presence by this author at the project site was 
also found to be a strength of the policy implementation.   
 Weaknesses.   Provider adherence to the policy was a weakness found in the 
implementation process.  The patient education was time consuming for the staff.  This may be a 
component of the 77% of the patients receiving the education compared to the goal of 100% 
adherence.   
Project Limitations 
          One of the project limitations includes provider adherence to the policy.  One provider in 
the practice was not in agreement with the risk assessment of patients on opioid medication with 
the use of the universal precautions model.   The belief of the provider was that the risk is not 
present for patients on low-dose opioids.  Low dose opioid medications are those with less than 
the equivalent of forty milligrams of morphine for the DNP project site.    
 A second limitation for the DNP project was the number of schedule II versus schedule 
III medications prescribed at the project site.  This number does vary dependent on the provider 
in the clinic.  For risk reduction and decrease patient harm, schedule III prescriptions should be 
included in the future in the policy for this patient population due to the opioid properties present 
in these medications.   
CO-PRESCRIBING NALOXONE POLICY 63 
 An unexpected limitation for the DNP project was the COVID-19 health pandemic 
occurred in the midst of project implementation.  The health pandemic changed how patient care 
was provided, including telehealth visits rather than face-to-face visits impacting the data 
collection and the number of patients seen in the DNP project site clinic.   
Project Benefits 
          The benefit of this DNP project includes harm reduction in the chronic pain patient 
population.  The cost of the project is minimal to implement the policy and is dependent on the 
amount of education material in the opioid packet.  The magnet in the education packet used in 
this project was the costliest component, however, can be omitted if the cost is too significant 
without changing the project outcomes.  The overall project benefits to the site include harm 
reduction in the chronic pain patient population and quality of care improvement.  The use of the 
universal precautions model from infectious disease removes the provider barriers, including 
time constraints for risk assessment in a patient visit.   
Practice Recommendations 
          To facilitate change for the project site and organization recommendations to improve 
provider and staff education before and during the policy implementation are essential for 
adherence to achieve the goal of 100% of the patient population receiving the opioid packet and 
naloxone education.  Beyond the time commitment for increased education, the cost remains low 
for policy implementation.   
 The policy can be improved before dissemination into the other clinical practice sites to 
include schedule II and schedule III medications.  This inclusion of both schedule II and III 
medications enables the policy to capture a greater portion of the chronic pain population at risk 
CO-PRESCRIBING NALOXONE POLICY 64 
for increased harm. Ultimately, the goal is for all patients with an opioid prescription to have 
naloxone available for emergencies.   
 Future policy implementation may benefit from additional information, including the 
barriers for the patients filling the prescription for naloxone.   The medication may be costly or 
not covered by insurance.  An addition to the policy may include filling the provided naloxone 
prescription as part of the care plan as a requirement when treating chronic pain with opioid 
medication.   The patient potentially could be required to bring the naloxone to each visit as 
documentation, similar to what is done with the opioid medication for pill counts.   
Final Summary 
Opioid overdose and misuse have been identified by Healthy People 2020 as one of the 
goals for harm reduction in the chronic pain patient population to decrease the number of opioid-
related overdose deaths.  This DNP project addresses harm reduction for the chronic pain 
population maintained on opioid medications through a quality improvement project policy 
implementation.  The concept of applying the universal precautions model to co-prescribe 
naloxone to each patient that receives an opioid prescription has the potential for harm reduction.  
It removes the barrier of providers assessing risk potential for an individual patient.  The post 
policy implementation survey reveals that although 77% of the patients received education 
regarding the risks of opioid medication and naloxone, only 33% of the patients filled the 
naloxone prescription.   Prior to further dissemination, identifying the patient barriers to filling 
the naloxone may be beneficial in addition to further education for providers and nursing staff.  
Although the goal of 100% was not achieved, significant harm reduction was accomplished for 
the chronic pain population.    
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Appendix A: PRISMA Flow Diagram 












































Figure 1.  PRISMA Flow Diagram shows the process of the literature search accomplished for 
the literature review for co-prescribing naloxone to chronic pain patients on opioid therapy 
(Moher, Liberati, Tetzlaff & Altman, 2009).   
Records identified through 
database searching ECU Laupus 
Library One Bar Search  (n=16) 
 



























Additional records identified 
through Google Scholar 
(n = 53 ) 
Records after duplicates removed 
(n = 37 ) 
Records screened 
(n = 37  ) 
Records excluded 
(n = 6  ) 
Full-text articles assessed 
for eligibility 
(n = 31  ) 
Full-text articles excluded, 
with reasons 
(n = 19  ) 
Reasons for exclusion include: 
 Out of date range 
 English not the primary 
language 
 Universal Precautions did not 
apply directly to the 
management of pain 
Studies included in 
qualitative synthesis 
(n = 7  ) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 1 ) 
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Appendix B:  Literature Matrix 
Figure 2.  Literature Review Matrix 
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Student: Margaret Dillon Date of Submission: September 25, 2018 
  
Faculty:  Dr. Reilly   
  
Co-Prescribing Naloxone Policy for Chronic Pain Patients on Opioid Therapy 
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Citation) 
Level of 
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(I to VII) 
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and relevance to your 
project and other 
information that you 
would like to make note 
of) 
Adler, J. A. and Mallick-Searle, T.  (2018).  An 
overview of abuse-deterrent opioids and 
recommendation for practical patient care.  Journal of 
Multidisciplinary Healthcare, 11, 323-332.   
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prescribing abuse deterrent opioids 
including evaluating risk factors and 
co-prescribing naloxone based on 
risk evaluation.  
Risk is difficult to assess, and over 53% of the pain relievers 
misused were given to, bought from or took from a friend to 
relative, highlighting the importance of opioid medications are 
not always misused by the patients that are prescribed the 
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Comprehensive risk 
management of patients 
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opioid medication 
needs to be recognized 
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training on critical 
issues is a barrier to this 
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prescribing of naloxone.  
CO-PRESCRIBING NALOXONE POLICY 72 
Costello, M. and Thompson, S. (2015).  Preventing 
Opioid Misuse and Potential Abuse:  The Nurse’s Role 
in Patient Education.  Pain Management Nursing, 16 
(4), 515-519.   
Level VI 
The lack of knowledge from nursing 
and lack of sufficient information 
affect the ability to provide useful 
medication instructions to patients 
receiving opioid medications.   
The lack of knowledge does not provide that patient with 
adequate knowledge about the risks of this class of medication 
and overdose potential.   
Although naloxone in 
this small study, it does 
reinforce that improved 
patient education can 
produce positive 
outcomes related to the 
knowledge of opioid 
medication use. 
Dowell, D., Haegerich, T. M., Chou, R.  (2016).  CDC 
Guidelines for Prescribing Opioids for Chronic Pain- 
United States, 2016.  Journal of the American Medical 
Association, 315(15), 1624-1645.  Clinical Review and 
Education Special Communication.   
Doi:10.1001/jama.2016.1464. 
Level I 
Evidence-based guidelines for 
prescribing opioids to the chronic 
pain patient. 
The guidelines include evaluating the patient for risk factors 
and prescribing naloxone when appropriate or when risk 




naloxone for patients 
with identified risk 
factors; however, it 
does not identify the 
best way to evaluate 
risks; this is a 
significantly limiting 
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difficulty of assessing 
the patient for risk 
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visit.  There are limiting 
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friends or relatives of the study 
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recognize the ability to reverse 
overdoses; however, barriers were 
identified as acceptance of naloxone 
prescribing.    
Barriers to naloxone prescribing include cost, expiration, lack 
of presence of someone to administer the naloxone, ability to 
identify an overdose, ability to administer the medication, fear 
of inducing pain, fear of withdrawal, fear of drug interactions 
or an adverse event.   
This article identifies 
the barriers and 
limitations currently 
with prescribing 
naloxone to chronic 
pain patients.  The 
education of patients 
and providers is the key 
to overcoming the 
barriers in this study.    
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Level I 
People at risk for overdose and other 
bystanders are willing and able to be 
trained on how to administer 
naloxone to prevent overdoses.   
Counseling patients on the risks of opioid overdose and 
prescribing naloxone has the potential to reduce fatalities and 
enhance safe opioid prescribing.   
This article strengthens 
the needs for naloxone 
prescribing policy for 
all patients receiving 
chronic opioid 
medications, 
highlighting that patient 
education is an essential 
component.  This needs 
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DNP project with 
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Takeda, M. Y., Katzman, J. G., Dole, E., Bennett, M. 
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A universal precautions model was 
used to prescribe naloxone in a 
specialty clinic, and after the 
naloxone rescue kits were dispensed 
at the seven months follow up, no 
overdoses had occurred. 
Universal prescribing for naloxone to all patients of chronic 
opioid therapy had a significant impact on harm reduction and 
decrease in overdose deaths.   
This article strongly 
supports the universal 
precautions prescribing 
model for naloxone in 
harm reduction in this 
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Co-Prescribing Naloxone Policy 
The recent opioid epidemic has led to an increase in opioid related overdoses.  Research has 
shown that co-prescribing naloxone to patients receiving opioid medication has decreased the 
amount of opioid related deaths.  Therefore, this policy is to address the need for prescribing 
naloxone to each of our patients receiving and opioid medication by utilizing the universal 
precautions model from infectious disease.  This ensures that each patient receives the education 
and the prescription regardless of risk assessment, provider knowledge of naloxone or targeting 
specific patients.   
Policy Implementation Date: January 23, 2020 
Date of Policy:  September 21, 2019 
POLICY: Each of these patients identified by the nursing staff as receiving an opioid medication 
will then receive an opioid packet prior to discharge.  Within the opioid packet will be the 
prescription for naloxone from the provider, naloxone education and instruction, and SAMSHA 
information for patients and family members on opioid medication.  Nursing staff will review 
with the patient the information and answer any questions or concerns of the patient.  
Universal Precautions Model: The application to each patient of the same level of precaution 






Policy for Chronic Pain 
Patients on Opioid Medication  
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Appendix D: Site Approval Letter 
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Appendix E:  Project Budget 
   DNP PROJECT 
BUDGET 




Patient Education Packet    
Two pocket folder 250 $0.49 $122.50 
Naloxone instruction document- 2 pages 500 $0.10/page $50.00 
Opioid safety document- 6 pages 250 $0.10/page $150.00 
Magnet 250 $0.57  $142.50 
Business card 250 $0.15 $37.50 
Policy Provider Education Meeting     
Policy documents- 2 pages 20 $0.10 $2 
Staff coffee & donuts- two dozen and one coffee 
carafe  from dunkin donuts  1    $40 
Nursing staff hourly wage 4 $24 $96 
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Appendix F: IRB Waiver 
Quality Improvement/Program Evaluation Self-Certification Tool 
 
Purpose: 
Projects that do not meet the federal definition of human research pursuant to 45 
CFR 46 do not require IRB review. This tool was developed to assist in the 
determination of when a project falls outside of the IRB's purview. 
 
Instructions: 
Please complete the requested project information, as this document may be 
used for documentation that IRB review is not required. Select the appropriate 
answers to each question in the order they appear below. Additional questions 
may appear based on your answers. If you do not receive a STOP HERE 
message, the form may be printed as certification that the project is "not 
research", and does not require IRB review. The IRB will not review your 
responses as part of the self-certification process. 
 
Name of Project Leader: Margaret Dillon 
 
Project Title: Co-Prescribing Naloxone Policy for Chronic Pain Patients on Opioid Therapy 
 
Brief description of Project/Goals: 
The proposed DNP project is to implement a policy for providers to prescribe naloxone to 
chronic pain patients receiving opioid therapy utilizing the universal precautions model. The 
goal is to decrease the risk of potential overdose and adverse outcomes for patients on 
opioids and in the community. By using a universal precautions model for this policy, the 
difficulty of accessing accurate patient risk factors is removed, the provider education for 
naloxone prescribing is improved and this model will remove the possibility of a patient 
interpreting the naloxone as a negative or personal risk factor. The providers will participate 
in an education session for the policy and naloxone. Once the policy is then implemented 
data will be collected to determine if the policy is being followed and each patient is 
prescribed the naloxone with education and filling the prescription. The site for the proposed 
DNP project is a pain clinic in Greenville, North Carolina, East Carolina Pain Consultants. 
 
Will the project involve testing an experimental drug, device (including medical 
software or assays), or biologic? 
no 
Has the project received funding (e.g. federal, industry) to be conducted as a 
human subject research study? 
no 
Is this a multi-site project (e.g. there is a coordinating or lead center, more than 
one site participating, and/or a study-wide protocol)? 
no 
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Is this a systematic investigation designed with the intent to contribute to 
generalizable knowledge (e.g. testing a hypothesis; randomization of subjects; 
comparison of case vs. control; observational research; comparative 
effectiveness research; or comparable criteria in alternative research 
paradigms)? 
no 
Will the results of the project be published, presented or disseminated outside of 
the institution or program conducting it? 
yes 
Would the project occur regardless of whether individuals conducting it may 
benefit professionally from it? 
yes 
Does the project involve "no more than minimal risk" procedures (meaning the 
probability and magnitude of harm or discomfort anticipated are not greater in 
and of themselves than those ordinarily encountered in daily life or during the 
performance of routine physical or psychological examinations or tests)? 
yes 
Is the project intended to improve or evaluate the practice or process within a 





Based on your responses, the project appears to constitute QI and/or Program 
Evaluation and IRB review is not required because, in accordance with federal 
regulations, your project does not constitute research as defined under 45 CFR 
46.102(d). If the project results are disseminated, they should be characterized 
as QI and/or Program Evaluation findings. 
 
Finally, if the project changes in any way that might affect the intent or design, 
please complete this self-certification again to ensure that IRB review is still not 
required. Click the button below to view a printable version of this form to save 
with your files, as it serves as documentation that IRB review is not required for 
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Appendix G:  Data Collection Tool 
Co-Prescribing Naloxone Policy for Chronic Pain Patients 
on Opioid Therapy 
Please answer the questions to the best of your ability.  If you have any questions please ask the Nursing staff.   






f. 71 and over  
2. What is your gender? 
a. male 
b. female 
c. other/prefer not to answer 
3.  What is your education level? 
a. Some high school 
b. High school graduate 
c. Some college 
d. College graduate 
e. Graduate degree 
4.  Have you been prescribed naloxone from this clinic? 
a. Yes 
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b. No 
5. Did you receive an opioid packet with patient education materials for opioid medications that included 
naloxone education, when and how to use it? 
a. Yes 
b. No 
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Appendix H: Excel Spreadsheet for Data Management 
Post Policy Implementation Survey  
Demographics  
Age  
 18-30 (1) 
 31-40 (2) 
 41-50 (3) 
 51-60 (4) 
  61-70 (5) 
 70 and over (6) 
Gender  
 Male (1) 
 Female (2) 
 Other (3) 
Education  
 some high school (1) 
 high school graduate (2) 
 some college (3) 
 college graduate (4) 
 graduate degree (5) 
Project Specific Questions  
Have you been prescribed naloxone from this clinic?  
 Yes (1) 
 No (2) 
Did you receive an opioid packet with patient education regarding opioids 
that included education of how and when to use naloxone?  
 Yes (1) 
 No (2) 
Did you fill the prescription for naloxone?  
 Yes (1) 
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Appendix I:  PRECEDE-PROCEED Model 
 
 
 
 
